Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Two candidate downstream target genes for E2A-HLF

H Kurosawa1, K Goi, T Inukai

  • 1Department of Experimental Oncology and the Center for Biotechnology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.

Blood
|December 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

Leukemia·2017
Same author

The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.

Oncogene·2017
Same author

Zebrafish models of leukemia.

Methods in cell biology·2017
Same author

Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.

Leukemia·2016
Same author

Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.

Oncogene·2016
Same author

Studying the peripheral sympathetic nervous system and neuroblastoma in zebrafish.

Methods in cell biology·2016

The E2A-HLF fusion gene drives leukemia by inhibiting apoptosis. Researchers identified two upregulated genes, ANNEXIN VIII and SRPUL, which may play paraneoplastic roles in leukemia.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The E2A-HLF fusion gene, resulting from t(17;19) translocation, is implicated in B-cell precursor leukemic transformation.
  • This transformation is hypothesized to occur via repression of a conserved apoptotic pathway.

Purpose of the Study:

  • To identify downstream targets of the E2A-HLF oncoprotein in t(17;19)+ pro-B leukemia cells.
  • To investigate the role of these targets in the leukemic process.

Main Methods:

  • Utilized a zinc-inducible dominant-negative E2A-HLF suppressor in UOC-B1 leukemia cells.
  • Employed representational difference analysis to identify differentially expressed mRNAs.
  • Subcloned and characterized upregulated cDNA fragments (F-5 and G-4).

Related Experiment Videos

Main Results:

  • Identified two E2A-HLF-upregulated transcripts: ANNEXIN VIII (F-5) and a novel protein SRPUL (G-4).
  • Transcript levels decreased significantly upon suppression of E2A-HLF DNA-binding activity.
  • ANNEXIN VIII and SRPUL were specifically expressed in UOC-B1 cells and not other leukemia lines, with SRPUL also found in normal heart, ovary, and placenta.

Conclusions:

  • ANNEXIN VIII and SRPUL do not directly prevent apoptosis in pro-B cells.
  • These proteins may have paraneoplastic roles in E2A-HLF-expressing leukemias, potentially contributing to symptoms like DIC and hypercalcemia.